Secondary erythrocytosis in patient with acromegaly
https://doi.org/10.14341/2071-8713-5303
Abstract
A 53-year old man with acromegaly was referred for neurosurgical treatment. At admission: growth hormone (GH) 240 ME/l at all
time points of glucose tolerance test, IGF-1 - 415,1 ng/ml, brain MRI showed pituitary adenoma 34×32×27 mm extending suprasellar,
deforming and displacing optic chiasm, parasellar to both cavernous sinuses and surrounding left internal carotid artery. Clinical blood
tests revealed marked erythrocytosis - 6.1×1012, Hb - 200 g/l, HCT - 62%; urobilinigen 50 mmol/l was found in urine; otherwise the tests
were normal. For exclusion of erythraemia the patient underwent trepanobiopsy of bone marrow which showed normal haemopoesis and
suggested a secondary nature of erythrocytosis. In preoperative period 1100 ml of blood were evacuated by phlebotomy in 4 sessions, which
resulted in reduction of erythrocyte count to 5,1×1012, Hb 160 g/l, HCT 50% and disappearance of urobilinigen. The patient was then operated
by transnasal approach with debulking of most adenomatous tissue but without biochemical remission of acromegaly (GH 92-99 at
glucose tolerance test). A week after surgery - erythrocytes 4,5×1012, Hb - 141 g/l, HCT - 44,1%. The patient was prescribed a octreotide
depo (Sandostatin LAR) injections 20 mg/mth and at 6 months from operation was feeling well, with clinical remission of acromegaly and
normalization of IGF-1 and all blood count parameters.
time points of glucose tolerance test, IGF-1 - 415,1 ng/ml, brain MRI showed pituitary adenoma 34×32×27 mm extending suprasellar,
deforming and displacing optic chiasm, parasellar to both cavernous sinuses and surrounding left internal carotid artery. Clinical blood
tests revealed marked erythrocytosis - 6.1×1012, Hb - 200 g/l, HCT - 62%; urobilinigen 50 mmol/l was found in urine; otherwise the tests
were normal. For exclusion of erythraemia the patient underwent trepanobiopsy of bone marrow which showed normal haemopoesis and
suggested a secondary nature of erythrocytosis. In preoperative period 1100 ml of blood were evacuated by phlebotomy in 4 sessions, which
resulted in reduction of erythrocyte count to 5,1×1012, Hb 160 g/l, HCT 50% and disappearance of urobilinigen. The patient was then operated
by transnasal approach with debulking of most adenomatous tissue but without biochemical remission of acromegaly (GH 92-99 at
glucose tolerance test). A week after surgery - erythrocytes 4,5×1012, Hb - 141 g/l, HCT - 44,1%. The patient was prescribed a octreotide
depo (Sandostatin LAR) injections 20 mg/mth and at 6 months from operation was feeling well, with clinical remission of acromegaly and
normalization of IGF-1 and all blood count parameters.
References
1. Ang S.O., Chen H., Gordeuk V.R. et al. Endemic polycythaema in Russia: mutation in the VHL gene // Blood Cells Molecular Dis. - 2002. - № 28. - Р. 57-62.
2. Gordeuk V.R., Sergueeva A.I., Miasnikova G.Y. et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythamia VHL mutation with thrombosis and vascular abnormalities but not tumors // Blood. - 2004. - № 103. - Р. 3924-3929.
3. McMullin M.F., Bareford D., Campbell P. et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis // Br J Haematol. - 2005. - № 130. - Р. 174-195.
4. Pearson T.C., Wetherley-Main G., Vascular occlusive episodes and venous haematcrite in primary proliferative polycythaemia // Lancet. - 1978. - № 2. - Р. 1219-1222.
5. Persy M.J., Genetically heterogenous origins of idiopathic erythrocytosis // Haematology. - 2007. - № 12. - Р. 131-139.
6. Sergueeva A.I., Miasnikova G.Y., Okhoti D.J. et al. Elevated homocystein, glutathione and cysteinylglycine concentrations in patients homozygouse for the Chuvash polycythaemia VHL mutation // Haematologica. - 2008. - № 93. - Р. 279-282.
Review
For citations:
, , , Secondary erythrocytosis in patient with acromegaly. Obesity and metabolism. 2011;8(4):44-48. (In Russ.) https://doi.org/10.14341/2071-8713-5303
Views:
818
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
